FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.
What happened
FDA conducted an unannounced inspection from November 28 to December 4, 2025, at the Alathur, Tamil Nadu, facility. Investigators found cracked, taped, and deteriorating gaskets, rust-like residues on product-contact surfaces, cracked parts, and wet paint during production, while maintenance records said the equipment was “ok.” They also found water condensation and drips onto production areas and standing water, with drums and sheeting used to manage leaks.
What FDA found
The firm did not adequately maintain API manufacturing equipment; investigators saw cracked, taped, and deteriorating gaskets, rust-like residues on product-contact surfaces, and cracked parts.
The firm’s maintenance and cleaning records marked the same deteriorated equipment as “ok,” contradicting observed conditions.
The firm did not maintain buildings and facilities in good repair; water condensed and dripped onto production areas and standing water formed near equipment.
The firm used temporary drums and sheeting to manage water drips instead of correcting the facility problem.
The firm’s investigations did not test equipment residues or retain samples to assess product quality impact.
The firm had procedures and checklists, but its quality system did not detect or proactively address obvious maintenance issues.
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective action plans, an independent review, retain-sample testing to assess affected U.S. batches, and evidence of repairs. FDA also recommends a qualified CGMP consultant and may withhold approvals or refuse imports until corrections are confirmed.
Who should pay attention
- brands and drugmakers that use Alchymars APIs
- U.S. applicants listing the site as a drug manufacturer
- API distributors and suppliers handling its products
This is a summary. Read the original letter on fda.gov.